Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients

Michał Bieńkowski, Sylwester Piaskowski, Ewelina Stoczyńska-Fidelus, Małgorzata Szybka, Mateusz Banaszczyk, Monika Witusik-Perkowska, Emilia Jesień-Lewandowicz, Dariusz J Jaskólski, Anna Radomiak-Załuska, Dorota Jesionek-Kupnicka, Beata Sikorska, Wielisław Papierz, Piotr Rieske and Paweł P Liberski

PLOS ONE, 2013, vol. 8, issue 6, 1-10

Abstract: Glioblastoma is a highly aggressive tumour of the central nervous system, characterised by poor prognosis irrespective of the applied treatment. The aim of our study was to analyse whether the molecular markers of glioblastoma (i.e. TP53 and IDH1 mutations, CDKN2A deletion, EGFR amplification, chromosome 7 polysomy and EGFRvIII expression) could be associated with distinct prognosis and/or response to the therapy. Moreover, we describe a method which allows for a reliable, as well as time- and cost-effective, screening for EGFR amplification and chromosome 7 polysomy with quantitative Real-Time PCR at DNA level. In the clinical data, only the patient’s age had prognostic significance (continuous: HR = 1.04; p

Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0065444 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 65444&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0065444

DOI: 10.1371/journal.pone.0065444

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().